Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | August 25, 2025 | August 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 25, 2025 · Filed August 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,559 |
Ending reported balance
After 2025-08-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-25 · Exercise / conversion · Acquired 17,040 · Balance 61,599 Row 2 · 2025-08-25 · Sale · Disposed 17,040 · Balance 44,559 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.84 · Expires 2025-10-28 | Direct | 0 |
Reported balance
After 2025-08-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-25 · Exercise / conversion · Disposed 17,040 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-27 | Direct | 15,940 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 15,940 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2025-08-25 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,511 F2: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 17,040 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · derivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,040 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 17,040 | $56.36 | $960,388.03 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 17,040 | $21.84 | $372,153.60 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018030 · form4.xml · derivative · entry 11 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018030 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559 Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 20:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 10,400 | $76.98 | $800,627.36 |
DisclosureSEC source: 0001062993-24-006109 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,097 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.955 to $77.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 3,937 | $0.00 Strike: $61.51 | $0.00 |
DisclosureSEC source: 0001062993-23-019846 · form4.xml · derivative · entry 10 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,937 shares Expires 2033-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-019846 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,497 Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 8,939 | $80.32 | $717,959.03 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,872 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.09 to $80.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 16,000 | $22.95 | $367,200.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 16,000 | $21.85 | $349,600.00 |
DisclosureSEC source: 0001062993-23-017413 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 377 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-009442 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,811 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 865 | $0.00 Strike: $295.77 | $0.00 |
DisclosureSEC source: 0001415889-22-010915 · form4-10312022_021026.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 Underlying: Common Stock · 865 shares Expires 2032-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 21:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010915 · form4-10312022_021026.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,297 Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 633 | $0.00 Strike: $515.24 | $0.00 |
DisclosureSEC source: 0000914190-21-000398 · edgar.xml · derivative · entry 10 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires 2031-10-28 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/28/2021) or the date of Bio-Techne's 2022 annual meeting of shareholders. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 194 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000398 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,959 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · derivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,000 | $481.52 | $1,926,064.80 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,000 | $70.35 | $281,400.00 |
DisclosureSEC source: 0000914190-21-000308 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,000 | $385.08 | $2,310,481.20 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,000 | $70.35 | $70,350.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006492 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006492 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,765 Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $60.46 | $0.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 8,347 | $219.33 | $1,830,730.82 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,374 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.0426 to $219.9846, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $61.46 | $307,300.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 29, 2019 16:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,000 | $60.46 | $604,600.00 |
DisclosureSEC source: 0000914190-19-000428 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000012 · edgar.xml · derivative · entry 12 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000012 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,721 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004306 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004306 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,226 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003376 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003376 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000861 · edgar.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000861 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.